HPV vaccine

Cervical Cancer Market is Expected to Increase With a CAGR of 16.9% for the Study Period of 2017-2030 in 7MM: DelveInsight

Thursday, September 17, 2020 - 3:30pm

An increase in cervical cancer incidence is also a major reason behind the accelerated momentum of the cervical cancer market size growth.

Key Points: 
  • An increase in cervical cancer incidence is also a major reason behind the accelerated momentum of the cervical cancer market size growth.
  • Some of the key insights from cervical cancer market report:
    The incidence of cervical cancer in 7MM (US, UK, Germany, Italy, Spain, France & Japan) in 2020 is expected to be 43,712.
  • Get a cervical cancer sample copy or download a cervical cancer infograph: www.delveinsight.com/sample-request/cervical-cancer-market
    Cervical cancer is a cause of infection from Human papillomavirus (HPV), which can be prevented.
  • The cervical cancer market also homes Merck's star, Keytruda, which got approval in 2018 for advanced cervical cancer for PD-L1 positive patients.

Cervical Cancer Market is Expected to Increase With a CAGR of 16.9% for the Study Period of 2017-2030 in 7MM: DelveInsight

Thursday, September 17, 2020 - 3:30pm

An increase in cervical cancer incidence is also a major reason behind the accelerated momentum of the cervical cancer market size growth.

Key Points: 
  • An increase in cervical cancer incidence is also a major reason behind the accelerated momentum of the cervical cancer market size growth.
  • Some of the key insights from cervical cancer market report:
    The incidence of cervical cancer in 7MM (US, UK, Germany, Italy, Spain, France & Japan) in 2020 is expected to be 43,712.
  • Get a cervical cancer sample copy or download a cervical cancer infograph: www.delveinsight.com/sample-request/cervical-cancer-market
    Cervical cancer is a cause of infection from Human papillomavirus (HPV), which can be prevented.
  • The cervical cancer market also homes Merck's star, Keytruda, which got approval in 2018 for advanced cervical cancer for PD-L1 positive patients.

Baum Hedlund Files Gardasil Lawsuit Against Merck on Behalf of Man

Thursday, September 17, 2020 - 12:56am

ORANGE COUNTY, Calif., Sept. 16, 2020 /PRNewswire/ -- Baum Hedlund Aristei & Goldman filed aGardasil vaccine injury lawsuit today against manufacturer Merck on behalf of a young man who sustained life-altering injuries he alleges were caused by the HPV vaccine.

Key Points: 
  • ORANGE COUNTY, Calif., Sept. 16, 2020 /PRNewswire/ -- Baum Hedlund Aristei & Goldman filed aGardasil vaccine injury lawsuit today against manufacturer Merck on behalf of a young man who sustained life-altering injuries he alleges were caused by the HPV vaccine.
  • But Merck knew that Gardasil was neither safe nor effective at preventing cervical cancer, and worse, the company knew that Gardasil could cause a host of serious health issues."
  • Baum Hedlund Aristei & Goldmanis one of the nation's leading law firms representing victims who have sustained injuries after receiving the Gardasil HPV vaccine .
  • Since 1973, Baum Hedlund Aristei & Goldman has won over $4 billion in settlements and verdicts on behalf of clients across all areas of practice.

HOOKIPA Pharma’s LCMV-based Immunotherapy for HPV16+ Cancers Demonstrates High Immunogenicity, According to Peer Reviewed Article

Wednesday, September 16, 2020 - 12:45pm

It is currently in Phase 1/2 clinical trials (NCT04180215) for HPV16+ cancers alone and in combination with an approved checkpoint inhibitor.

Key Points: 
  • It is currently in Phase 1/2 clinical trials (NCT04180215) for HPV16+ cancers alone and in combination with an approved checkpoint inhibitor.
  • HPV-associated cancers, especially head and neck cancers, remain a significant health concern, as no curative therapies are currently available.
  • Human Papillomavirus, or HPV, is estimated to cause about 5% of the worldwide burden of cancers.
  • This includes approximately 99% of cases in cervical, up to 60% of head and neck, 70% of vaginal and 88% of anal cancers.

Public flu shots offered Sept. 25 – 27, 9 am – 3 pm, at the Minnesota State Fair grounds

Monday, September 14, 2020 - 9:38pm

Flu shots will be administered by nurses with Hennepin Healthcares Worksite Wellness program.

Key Points: 
  • Flu shots will be administered by nurses with Hennepin Healthcares Worksite Wellness program.
  • Two types of flu vaccine are available: Quadrivalent vaccine for people between 6 months-64 years and High Dose vaccine for people age 65 and older.
  • If someone is uninsured, they will receive a free flu shot through the MnVFC (Minnesota Vaccine for Children) or UUAV (Uninsured and Underinsured Adult Vaccine) state program.
  • Health Fair 11s Flu Fighter Clinics are made possible with additional support from Hennepin Healthcare and the Minnesota State Fair.

New Research Suggests How to Message the Eventual COVID-19 Vaccine in the US

Wednesday, September 9, 2020 - 5:07pm

Highlighting the story of an individual who was impacted by COVID-19 was, by far, the most effective message theme.

Key Points: 
  • Highlighting the story of an individual who was impacted by COVID-19 was, by far, the most effective message theme.
  • The HPV research also found that a message about vaccine safety is ineffective, despite people reporting "safety" as the biggest concern about vaccination.
  • Although personal stories were effective for both flu and COVID-19 vaccine messaging, the "community" theme was most persuasive in the flu research , but ineffective for the COVID vaccine.
  • This reinforces that we can't repurpose flu vaccine marketing messages for the eventual COVID vaccine.

Vaxart, Inc. to Participate in September Virtual Investor Conferences

Thursday, September 3, 2020 - 1:00pm

A link to the webcasts along with a replay of the webcasts will be accessible on the Events & Presentations page of the Investors section on the Companys website.

Key Points: 
  • A link to the webcasts along with a replay of the webcasts will be accessible on the Events & Presentations page of the Investors section on the Companys website.
  • Vaxart is a clinical-stage biotechnology company focused on developing oral tablet vaccines designed to generate mucosal and systemic immune responses that protect against a wide range of infectious diseases and has the potential to provide sterilizing immunity for diseases such as COVID-19.
  • Vaxarts development programs include oral tablet vaccines that are designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV).
  • For more information, please visit www.vaxart.com.

WebMD Poll: More than half will get Covid-19 vaccine in first year, 42% in first six months

Wednesday, September 2, 2020 - 3:28pm

Fewer than one-third say they will get the vaccine in the first three months, which is consistent in both polls.

Key Points: 
  • Fewer than one-third say they will get the vaccine in the first three months, which is consistent in both polls.
  • In the new poll, about 12% said they will not get a vaccine at all, and the rest remain unsure.
  • Vaccine efficacy rates range from about 40% to 60% for the seasonal flu vaccine, to 97% for the measles, mumps and rubella vaccine, according to CDC data .
  • "Understanding how well the vaccine works could be a hurdle for patients," said John Whyte, MD, chief medical officer of WebMD.

Russia Registers First COVID-19 Vaccine - ResearchAndMarkets.com

Friday, August 14, 2020 - 9:03am

Russia has today become the first country to register a COVID-19 vaccine.

Key Points: 
  • Russia has today become the first country to register a COVID-19 vaccine.
  • In July, the World Health Organization reported that there were 26 vaccine candidates in the clinical evaluation stage including the vaccine registered in Russia.
  • The Russian Health Ministry intends to offer the vaccine first to healthcare workers, teachers and other high risk groups.
  • Mass production of the vaccine is set to begin in September with a mass vaccination drive planned for October.

China Human Vaccine Market Insights 2020-2026 Featuring In-Depth Profiles of 22 Companies

Friday, August 7, 2020 - 4:45pm

DUBLIN, Aug. 7, 2020 /PRNewswire/ -- The "China Human Vaccine Industry Report, 2020-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Aug. 7, 2020 /PRNewswire/ -- The "China Human Vaccine Industry Report, 2020-2026" report has been added to ResearchAndMarkets.com's offering.
  • Human vaccine industry in China (environments, status quo, market demand, market size, import & export, competition pattern);
    Human vaccine market segments in China (market demand, lot releases, competitive landscape);
    22 human vaccine companies (operation, vaccine business, etc.)
  • The Chinese human vaccine market is now occupied by local companies, where the state-owned enterprises command more than a half of the market.
  • Although the Chinese human vaccine market is ruled by local companies, the imported vaccines are largely the extra EPI vaccines (not free, and residents can choose whether they want to be inoculated) such as 13-valent pneumonia vaccine, HPV vaccine and DTaP-IPV/Hib vaccine.